SRPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available capital, Sarepta Therapeutics Inc (SRPT) is not a strong buy at the moment. The technical indicators are bearish, financial performance is weak, and there are no significant positive catalysts to offset the risks. Holding off on investing in SRPT until clearer positive signals emerge would be prudent.
The technical indicators for SRPT are bearish. The MACD is negative and contracting, the RSI is neutral at 29.153, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 15.864, with resistance levels at 17.285 and 18.706.
The Route 79 Duchenne Scholarship Program launch demonstrates the company's commitment to its community. Analysts still see potential in Sarepta's siRNA readout, which could provide a favorable setup.
The FDA's recent rejection of multiple drug applications raises regulatory concerns. Analysts have lowered price targets due to disappointing 2026 guidance and safety-related delays in product launches. Hedge funds are selling aggressively, and the company's financial performance has significantly deteriorated.
Sarepta's Q4 2025 financials show a significant decline in revenue (-32.73% YoY), net income (-359.18% YoY), EPS (-397.73% YoY), and gross margin (-87.68% YoY). These metrics indicate severe financial challenges.
Analyst sentiment is mixed to negative. Recent price target adjustments include Wedbush lowering its target to $29 (Outperform), Wells Fargo lowering to $38 (Overweight), and Citi maintaining a Sell rating with an $8 target. Analysts cite regulatory risks, competition, and safety-related delays as key concerns.
